Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
N Engl J Med. 2025 Jan 2;392(1):45-55.
https://pubmed.ncbi.nlm.nih.gov/39282902/
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
N Engl J Med. 2021 Jun 3;384(22):2102-2114.
https://pubmed.ncbi.nlm.nih.gov/34077643/
Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma
J Clin Oncol. 2025 Jan 20;43(3):329-338.
https://pubmed.ncbi.nlm.nih.gov/39356975/
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors
J Clin Oncol. 2025 Jan 20;43(3):251-259.
https://pubmed.ncbi.nlm.nih.gov/39411812/
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial
J Clin Oncol. 2025 Jan 10;43(2):189-200.
https://pubmed.ncbi.nlm.nih.gov/39303200/
Impact of an Epstein-Barr Virus Serology-Based Screening Program on Nasopharyngeal Carcinoma Mortality: A Cluster-Randomized Controlled Trial
J Clin Oncol. 2025 Jan;43(1):22-31.
https://pubmed.ncbi.nlm.nih.gov/39353160/
Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer
N Engl J Med. 2025 Jan 23;392(4):323-335.
https://pubmed.ncbi.nlm.nih.gov/39842010/
Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial
Lancet Oncol. 2025 Jan;26(1):37-50.
https://pubmed.ncbi.nlm.nih.gov/39675376/
Optimum radiation dose for palliation in head and neck squamous cell carcinoma (OpRAH) - A phase 3 randomized controlled trial
Radiother Oncol. 2025 Jan;202:110611.
https://pubmed.ncbi.nlm.nih.gov/39522825/
Long-Term Update of a Phase 3 Randomized Study Comparing Once-a-Week Versus Once-Every-3-Weeks Cisplatin Along With Radiation in Head and Neck Cancer
Int J Radiat Oncol Biol Phys. 2025 Jan 1;121(1):128-136.
https://pubmed.ncbi.nlm.nih.gov/39074566/
Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial
Lancet Oncol. 2025 Feb;26(2):187-199.
https://pubmed.ncbi.nlm.nih.gov/39848272/
Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial
Eur Urol. 2025 Feb;87(2):228-237.
https://pubmed.ncbi.nlm.nih.gov/39379238/
OPAR: A Randomized Trial of Partial Breast Irradiation in Five Fractions Once Daily for Early Breast Cancer
J Clin Oncol. 2025 Feb 10;43(5):505-512.
https://pubmed.ncbi.nlm.nih.gov/39378393/
Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years
J Clin Oncol. 2025 Feb 20;43(6):633-640.
https://pubmed.ncbi.nlm.nih.gov/39671537/
Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection
Eur Urol. 2025 Feb;87(2):253-260.
https://pubmed.ncbi.nlm.nih.gov/39472200/
Patient-Reported Outcomes Between Whole-Breast Plus Regional Irradiation and Whole-Breast Irradiation Only in pN1 Breast Cancer After Breast-Conserving Surgery and Taxane-Based Chemotherapy: A Randomized Phase 3 Clinical Trial (KROG 17-01)
Int J Radiat Oncol Biol Phys. 2025 Feb 1;121(2):341-351.
https://pubmed.ncbi.nlm.nih.gov/39326505/
Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial
J Clin Oncol. 2025 Feb;43(4):412-421.
https://pubmed.ncbi.nlm.nih.gov/39374473/
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial
JAMA Oncol. 2025 Feb 1;11(2):136-144.
https://pubmed.ncbi.nlm.nih.gov/39699905/
Mepitel® film versus standard care for the prevention of skin toxicity in breast cancer patients treated with adjuvant radiotherapy: A randomized controlled trial
Clin Transl Radiat Oncol. 2025 Feb 18;52:100936.
https://pubmed.ncbi.nlm.nih.gov/40110362/
A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial
Ann Oncol. 2025 Feb;36(2):208-215.
https://pubmed.ncbi.nlm.nih.gov/39532203/
Final Results of the GRECCAR-6 Trial on Waiting Period Following Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer: 5 Years of Follow-up
Dis Colon Rectum. 2025 Feb 1;68(2):199-208.
https://pubmed.ncbi.nlm.nih.gov/39508462/
External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Treatment of Inoperable Hepatocellular Carcinoma: A Randomized Phase 3 Trial
Int J Radiat Oncol Biol Phys. 2025 Feb 1;121(2):414-422.
https://pubmed.ncbi.nlm.nih.gov/39299550/
Prostate Cancer-related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial
Eur Urol. 2025 Mar;87(3):357-363.
https://pubmed.ncbi.nlm.nih.gov/39304427/
Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial
N Engl J Med. 2025 Mar 13;392(11):1051-1064.
https://pubmed.ncbi.nlm.nih.gov/39665649/
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma
J Clin Oncol. 2025 Mar 20;43(9):1055-1060.
https://pubmed.ncbi.nlm.nih.gov/39700442/
Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial
Eur Urol. 2025 Mar;87(3):314-323.
https://pubmed.ncbi.nlm.nih.gov/39271420/
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
Lancet Oncol. 2021 Aug;22(8):1081-1092.
https://pubmed.ncbi.nlm.nih.gov/34252374/
Analysis of patients with locally advanced rectal cancer given neoadjuvant radiochemotherapy with or without RT dose intensification: A multicenter retrospective study - ATLANTIS part I
Radiother Oncol. 2025 Mar;204:110701
https://pubmed.ncbi.nlm.nih.gov/40130646/
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial
J Clin Oncol. 2025 Mar 20;43(9):1073-1082.
https://pubmed.ncbi.nlm.nih.gov/39693584/
Bladder Adjuvant Radiation Therapy (BART): Acute and Late Toxicity From a Phase III Multicenter Randomized Controlled Trial
Int J Radiat Oncol Biol Phys. 2025 Mar 1;121(3):728-736.
https://pubmed.ncbi.nlm.nih.gov/39353477/
Ten-Year Outcomes of a Phase 3, Multicenter, Randomized Controlled Trial (SHIP0804) With 3-Month Neoadjuvant Androgen Deprivation Prior to 125I-Seed Transperineal Prostate Brachytherapy Followed by Nil Versus 9-Month Adjuvant Hormonal Therapy in Patients With Intermediate-Risk Prostate Cancer
Int J Radiat Oncol Biol Phys. 2025 Mar 15;121(4):875-884.
https://pubmed.ncbi.nlm.nih.gov/39551103/
Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial
Lancet Oncol. 2025 Apr;26(4):425-436.
https://pubmed.ncbi.nlm.nih.gov/40112851/
Toxicity and Efficacy of Different Target Volume Delineations of Radiation Therapy Based on the Updated Radiation Therapy Oncology Group/National Research Group and European Organization for Research and Treatment of Cancer Guidelines in Patients With Grade 3-4 Glioma: A Randomized Controlled Clinical Trial
Int J Radiat Oncol Biol Phys. 2025 Apr 1;121(5):1168-1181.
https://pubmed.ncbi.nlm.nih.gov/39615657/
StrataXRT and Mepitel Film for Preventing Postmastectomy Acute Radiation Dermatitis in Breast Cancer: An Intrapatient Noninferiority Randomized Clinical Trial
Int J Radiat Oncol Biol Phys. 2025 Apr 1;121(5):1145-1155.
https://pubmed.ncbi.nlm.nih.gov/39608611/
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer
J Clin Oncol. 2025 Apr 20;43(12):1474-1487.
https://pubmed.ncbi.nlm.nih.gov/39841939/
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
J Clin Oncol. 2025 Apr 20;43(12):1453-1462.
https://pubmed.ncbi.nlm.nih.gov/39778121/
Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: Primary analysis of the ORATOR2 randomized trial
Eur J Cancer. 2025 May 2;220:115343.
https://pubmed.ncbi.nlm.nih.gov/40121836/
A Study on Breast Cancer Patient Care Using Chatbot and Video Education for Radiation Therapy: A Randomized Controlled Trial
Int J Radiat Oncol Biol Phys. 2025 May 1;122(1):84-92.
https://pubmed.ncbi.nlm.nih.gov/39732344/
A Randomized Study of Consolidation Chemoradiotherapy Versus Observation After First-line Chemotherapy in Advanced Gallbladder Cancers: RACE-GB study
Int J Radiat Oncol Biol Phys. 2025 May 1;122(1):10-18.
https://pubmed.ncbi.nlm.nih.gov/39675683/
Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials
Ann Oncol. 2025 May;36(5):572-582.
https://pubmed.ncbi.nlm.nih.gov/39986927/
Impact of bra application in breast cancer radiotherapy: A pilot prospective randomized trial
Radiother Oncol. 2025 May;206:110785.
https://pubmed.ncbi.nlm.nih.gov/39952437/
Quality of Life and Functional Outcomes in Patients With Locally Advanced Rectal Cancer Receiving Total Neoadjuvant Therapy Versus Concurrent Chemoradiation Therapy: An Analysis of the STELLAR Trial
Int J Radiat Oncol Biol Phys. 2025 May 1;122(1):43-51.
https://pubmed.ncbi.nlm.nih.gov/39814105/
Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy
N Engl J Med. 2025 Jun 5;392(21):2113-2124.
https://pubmed.ncbi.nlm.nih.gov/40466065/
Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial
J Clin Oncol. 2025 Jun 20;43(18):2044-2048.
https://pubmed.ncbi.nlm.nih.gov/40367400/
Esophagus-sparing radiotherapy for complicated spinal metastases (ESO-SPARE). A randomized phase III clinical trial
Radiother Oncol. 2025 Jun;207:110906
https://pubmed.ncbi.nlm.nih.gov/40324910/
Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial
J Clin Oncol. 2025 Jun 10;43(17):1972-1983.
https://pubmed.ncbi.nlm.nih.gov/40249893/
Patterns of Relapse Following Radiation Therapy of Intermediate-Risk Prostate Cancer in the PROFIT Randomized Trial
Int J Radiat Oncol Biol Phys. 2025 Jun 1;122(2):399-406.
https://pubmed.ncbi.nlm.nih.gov/39914555/
Early toxicity of moderately hypofractionated radiation therapy in breast cancer patients receiving locoregional irradiation: First results of the UNICANCER HypoG-01 phase III trial
Radiother Oncol. 2025 Jun;207:110849.
https://pubmed.ncbi.nlm.nih.gov/40097073/
Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial
Eur Urol. 2025 Jun;87(6):622-625.
https://pubmed.ncbi.nlm.nih.gov/39537438/
Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study
Radiother Oncol. 2025 Jun;207:110915.
https://pubmed.ncbi.nlm.nih.gov/40379410/
Local recurrence with and without a tumour-bed boost: A post-hoc analysis of the DBCG IMN2 study
Radiother Oncol. 2025 Jun;207:110905.
https://pubmed.ncbi.nlm.nih.gov/40324911/
